Document Detail


Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
MedLine Citation:
PMID:  18065961     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
TMPRSS2-ERG gene fusion leading to the androgenic induction of the ERG proto-oncogene expression is a highly prevalent oncogenic alteration in prostate tumor cells. Prostate cancer is a multi-focal disease, and the origins as well as biological contribution of multiple cancer foci remain unclear with respect to prostate cancer onset or progression. To assess the role of TMPRSS2-ERG alteration in prostate cancer onset and/or progression, we have evaluated the status of fusion transcripts in benign glands, prostatic intraepithelial neoplasia (PIN) and multiple cancer foci of each prostate. Quantitative expression of TMPRSS2-ERG fusion type A and C transcripts was analyzed in benign, tumor and PIN areas, selected from whole-mount radical prostatectomy slides. TMPRSS2-ERG expression was correlated with clinicopathological features. Overall, 30 of 45 (67%) patients exhibited TMPRSS2-ERG fusion transcripts in at least one tumor focus. Of 80 tumor foci analyzed, 39 had TMPRSS2-ERG fusion (type A only: 30, type C only: 2, both types A and C: 7), with predominant detection of the TMPRSS2-ERG fusion type A (27/30, 90%) in the index tumors. Of 14 PIN lesions, 2 were positive for type A fusion. Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer. However, heterogeneity of the TMPRSS2-ERG detection in the context of multiple cancer foci and its frequency in PIN also support the role of other genomic alterations in the origins of prostate cancer.
Authors:
Bungo Furusato; Chun-Ling Gao; Lakshmi Ravindranath; Yongmei Chen; Jennifer Cullen; David G McLeod; Albert Dobi; Shiv Srivastava; Gyorgy Petrovics; Isabell A Sesterhenn
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2007-12-07
Journal Detail:
Title:  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc     Volume:  21     ISSN:  0893-3952     ISO Abbreviation:  Mod. Pathol.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-25     Completed Date:  2008-04-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806605     Medline TA:  Mod Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  67-75     Citation Subset:  IM    
Affiliation:
Department of Surgery, United States Military Cancer Institute, Center for Prostate Disease Research, Uniformed Service University of the Health Science, Bethesda, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / genetics*,  metabolism,  pathology
Cell Line, Tumor
Disease-Free Survival
Gene Expression Regulation, Neoplastic
Humans
Male
Microdissection
Middle Aged
Neoplasm Recurrence, Local
Oncogene Proteins, Fusion / genetics*,  metabolism
Precancerous Conditions / genetics*,  metabolism,  pathology
Prostate / metabolism,  pathology,  surgery
Prostate-Specific Antigen / blood
Prostatectomy
Prostatic Intraepithelial Neoplasia / genetics*,  metabolism,  pathology
Prostatic Neoplasms / genetics*,  metabolism,  pathology
RNA, Neoplasm / analysis
Reverse Transcriptase Polymerase Chain Reaction
Tumor Markers, Biological / metabolism
Grant Support
ID/Acronym/Agency:
R01 DK 065977/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Oncogene Proteins, Fusion; 0/RNA, Neoplasm; 0/TMPRSS2-ERG fusion protein, human; 0/Tumor Markers, Biological; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Next Document:  Conscious sedation for dentistry: an update.